Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test to differentiate between Covid-19 and common winter diseases.

Healthcare providers – including CVS Health Corp. – are kicking off flu vaccinations early, ordering extra shots and aiming to add tests that check for both the annual flu and COVID-19, pharmacy executives and experts told Reuters.

Critically ill Covid-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said on Sunday.

Merck is spinning off products from the company’s Women’s Health, Legacy Brands and Biosimilars businesses.

Prospects for AstraZeneca’s respiratory treatments business improved as a three-drug inhaler was shown to ease smoker’s lung and U.S. regulators granted the company’s injectable asthma drug Fasenra special status for a rare lung condition.

Research from three clinical trials supports that Sarepta Therapeutics’ Exondys 51 slows respiratory decline in DMD.

Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.

GlaxoSmithKline is significantly reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company made some cuts to the product pipeline, including six in GSK’s 2018 year-end report.

AstraZeneca filed a Worker Readjustment and Retraining Notification Act (WARN) notice with the State of Colorado, indicating plans to lay off 210 people in Boulder and Longmont.

The Nasdaq indicated that there was a record amount of biotech initial public offerings (IPOs) in 2018, totaling around $8.2 billion raised, breaking 2014’s record of $6.5 billion.